Other sleep disorders
Methodology & AI Transparency ⓘ
Other sleep disorders Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as G47.8, Other sleep disorders falls under Sleep Disorders management, where iron/thyroid screening [Other sleep disorders G47.8] establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Diagnostic registry G47.8: Other sleep disorders is managed within Sleep Disorders.
- 3 Typical cash cost range: Primary evaluation for Other sleep disorders incorporates iron/thyroid screening [Other sleep disorders G47.8] and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Other sleep disorders: Insomnia Severity Index in Other sleep disorders (G47.8: (ISI)) (< 7 (G47.8)) and Nocturnal Oxygen Saturation in Other sleep disorders (G47.8: (SpO2)).
Ask our AI Specialists anything about Other sleep disorders
What Is Other sleep disorders?
Designated in federal medical registries as G47.8, Other sleep disorders falls under Sleep Disorders management, where iron/thyroid screening [Other sleep disorders G47.8] establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in sleep disorders, Other sleep disorders (G47.8) involves sympathetic micro-arousals [Other sleep disorders G47.8]. progression correlates with shifts in Insomnia Severity Index in Other sleep disorders (G47.8: (ISI)) (< 7 (G47.8)).
Common Symptoms & Clinical Signs
- • Presentation of Other sleep disorders (G47.8): unrefreshing morning waking in Other sleep disorders (G47.8: despite adequate hours)
- • Secondary Other sleep disorders clinical sign: loud habitual snoring, in Other sleep disorders (G47.8: witnessed breathing pauses,)
- • Symptom flares in Other sleep disorders correlating with Insomnia Severity Index in Other sleep disorders (G47.8: (ISI)) deviation outside < 7 (G47.8)
- • Functional sleep disorders impact requiring iron/thyroid screening [Other sleep disorders G47.8] evaluation (G47.8)
Other sleep disorders Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G47.8 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Insomnia, Sleep Apnea & Sleep Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Insomnia Severity Index in Other sleep disorders (G47.8: (ISI)) | < 7 (G47.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Nocturnal Oxygen Saturation in Other sleep disorders (G47.8: (SpO2)) | >= 94% nadir > 90% (G47.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Ferritin (Restless in Other sleep disorders (G47.8: Legs)) | > 75 ng/mL (G47.8) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Other sleep disorders
Treatment selection for Other sleep disorders depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Other sleep disorders)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Valsartan vs. other angiotensin II receptor blockers in the treatment of high: What a 13,110-Participant Study Found Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential high blood pressure. International journal of clinical practice • 2009-05-15 • Meta-Analysis | N = 13,110 | 99/100 | PMID 19392925 ↗ |
| New Insights on Efficacy comparison of monotherapies and combination therapies for androgenetic: What a 3,133-Participant Study Found In recent years, combination therapies are showing significant promise as potential therapies. Dermatologic therapy • 2022-03-15 • Meta-Analysis | N = 3,133 | 99/100 | PMID 34897933 ↗ |
| New Insights on Combination Therapy in Androgenetic hair loss: A Network Meta-Analysis of: What a 3,012-Participant Study Found Based on the current studies, we found that the combination of Minoxidil with spironolactone, PRPF, flutamide, and finasteride may offer better treatment outcomes for patients with androgenetic hair loss. Aesthetic plastic surgery • 2026-07-15 • Meta-Analysis | N = 3,012 | 99/100 | PMID 42168420 ↗ |
| New Insights on Safety profile of telmisartan as single-drug treatment or combined with: What a 8,023-Participant Study Found The consolidated data show that telmisartan +/- HCTZ are well tolerated in patients of all ages and have placebo-like tolerabilities. Blood pressure. Supplement • 2008-06-15 • Randomized Controlled Trial | N = 8,023 | 96/100 | PMID 18705533 ↗ |
| New Insights on Telmisartan and amlodipine single-pill combinations vs amlodipine single-drug: What a 1,097-Participant Study Found Superior BP reductions were also seen with T40-T80/A5 vs A10, with BP goal rates at least as high as with A10; however, there was significantly more peripheral edema with A10 (27.2% vs 4.3% for pooled. Journal of clinical hypertension (Greenwich, Conn.) • 2011-07-15 • Randomized Controlled Trial | N = 1,097 | 96/100 | PMID 21762357 ↗ |
Other sleep disorders Patient Community & “People Like Me” Threads
Filter Other sleep disorders community threads and patient logs by age, biological sex, dosage, and treatment duration.